drugset
Drugs / Epstein-Barr virus-specific adoptive T-cells immunotherapy
last change Jan 2016 re-read 3 minutes ago

Epstein-Barr virus-specific adoptive T-cells immunotherapy

Cell therapy

Developed for
nasopharyngeal carcinoma
Investigated by
Brigham and Women's Hospital · Dana-Farber Cancer Institute

Trials 1

today NCT00431210 · Ph 1
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00431210 Feb 2007 → Jun 2015 nasopharyngeal carcinoma Dana-Farber Cancer Institute Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Epstein-Barr virus-specific adoptive T-cells immunotherapy ClinicalTrials.gov intervention name — accepted as the source's own label NCT00431210 ↗
Modality Cell therapy “The EBV immunotherapy product will contain T-cells that may react against your EBV-related tumor.” NCT00431210 ↗
Route Intravenous “EBV immunotherapy product will be given to the participant intravenously (infusion).” NCT00431210 ↗